Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional <i>Ex Vivo</i> Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

24 Jun 2014

Abstract excerpt

PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BRCA gene mutations is not always known and tumors can be HR deficient for other reasons than BRCA gene mutations. Therefore, we aimed to develop a functional test to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24963051
DOI: 10.1158/1078-0432.ccr-14-0571

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional <i>Ex Vivo</i> Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor TreatmentPMID 24963051Read ↗

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene DefectsSemantic proximity Read ↗

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-ProficientSemantic proximity Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationSemantic proximity Read ↗

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissueSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerSemantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor BlocksSemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerSemantic proximity Read ↗

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.